Ocular Therapeutix Inc (NAS:OCUL)
$ 11.0139 0.4139 (3.9%) Market Cap: 1.72 Bil Enterprise Value: 1.29 Bil PE Ratio: 0 PB Ratio: 4.53 GF Score: 66/100

Ocular Therapeutix Inc To Discuss Interim Data Update Call Transcript

Feb 13, 2023 / 01:30PM GMT
Release Date Price: $5.23 (+35.14%)
Operator

Ladies and gentlemen. Thank you for standing by. And welcome to Ocular Therapeutics in term 10-month data update from the ongoing U.S. Phase I clinical trial of OTX-TKI for the treatment of wet AMD. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker host Donald Notman, Chief Financial Officer. Please go ahead, sir.

Donald Notman
Ocular Therapeutix, Inc. - CFO

Thank you, Olivia. Good morning, everyone, and thank you for joining us on our conference call to discuss the interim 10 months results from our U.S.-based Phase I clinical trial of OTX-TKI for the treatment of wet AMD. The press release that we issued on Saturday and the slide deck with the interim results can be accessed on the Investors portion of our website at investors.ocutx.com.

Leading the call today will be Anthony Mattessich, our President and Chief Executive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot